{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:25:48Z","timestamp":1770899148779,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.critrevonc.2023.104034","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T11:47:22Z","timestamp":1685360842000},"page":"104034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety"],"prefix":"10.1016","volume":"188","author":[{"given":"Anshu","family":"Thakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshni S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"39\u201347","key":"10.1016\/j.critrevonc.2023.104034_bib1","article-title":"Efficacy and safety of aflibercept in combination with chemotherapy beyond second-line therapy in metastatic colorectal carcinoma patients: an AGEO multicenter study","volume":"19","author":"Auvray","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib2","article-title":"Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature","volume":"10","author":"Chan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2023.104034_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007047.pub2","article-title":"Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer","author":"Chan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2023.104034_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1053\/j.seminoncol.2017.07.004","article-title":"Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: a systematic review and pooled analysis","volume":"44","author":"Chebib","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JGO.19.00367","article-title":"Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline","author":"Chiorean","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/ajco.12496","article-title":"Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer","volume":"12","author":"Chong","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(10)60353-4","article-title":"Colorectal cancer","volume":"375","author":"Cunningham","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2023.104034_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2023.104034_bib9","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/cas.13943","article-title":"Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer","volume":"110","author":"Denda","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2023.104034_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fonc.2019.00142","article-title":"Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC","volume":"9","author":"El-Deiry","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jcpt.13610","article-title":"Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: a systematic review and PRISMA\u2010Compliant single\u2010arm Meta\u2010Analysis of noncomparative clinical studies and randomized controlled trials","volume":"47","author":"Ge","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2023.104034_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/526178","article-title":"Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept","volume":"2014","author":"Giordano","year":"2014","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.critrevonc.2023.104034_bib13","unstructured":"Globocon, \u3008https:\/\/gco.iarc.fr\/today\u3009, 2020, n.d."},{"key":"10.1016\/j.critrevonc.2023.104034_bib14","first-page":"1","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib15","doi-asserted-by":"crossref","first-page":"73009","DOI":"10.18632\/oncotarget.20314","article-title":"The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials","volume":"8","author":"Jang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2023.104034_bib16","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.clon.2022.02.011","article-title":"A comparison of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab and FOLFIRI plus aflibercept as second-line treatment for metastatic colorectal cancer","volume":"34","author":"Jo","year":"2022","journal-title":"Clin. Oncol. R. Coll. Radiol. G. B"},{"key":"10.1016\/j.critrevonc.2023.104034_bib17","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.2013.523","article-title":"Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer","volume":"109","author":"Joulain","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2015.329","article-title":"Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting","volume":"113","author":"Lambrechts","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib19","first-page":"285","article-title":"Aflibercept in combination with FOLFIRI as first-line chemotherapy in patients with metastatic colorectal cancer (mCRC): a phase II study (FFCD 1302","volume":"19","author":"Lapeyre-Prost","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2217\/fon-2017-0669","article-title":"Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study","volume":"14","author":"Li","year":"2018","journal-title":"Future Oncol. Lond. Engl."},{"key":"10.1016\/j.critrevonc.2023.104034_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2407-12-89","article-title":"Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups","volume":"12","author":"Macedo","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11523-019-00647-3","article-title":"MINOAS: a single-arm translational phase II Trial of FOLFIRI plus aflibercept as first-line therapy in unresectable, metastatic colorectal cancer","volume":"14","author":"Matikas","year":"2019","journal-title":"Target. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s12029-022-00900-5","article-title":"Oligometastatic colorectal cancer: a review of definitions and patient selection for local therapies","author":"Miller","year":"2023","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib24","article-title":"Second-line systemic therapy for metastatic colorectal cancer","volume":"2017","author":"Mocellin","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2023.104034_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canlet.2016.01.048","article-title":"Animal models of colorectal cancer with liver metastasis","volume":"387","author":"Oh","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2023.104034_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1758835921989223","article-title":"Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol","volume":"13","author":"Ottaiano","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib27","first-page":"e457","article-title":"Aflibercept plus FOLFIRI in the real-life setting: safety and quality of life data from the italian patient cohort of the aflibercept safety and quality-of-life program study","volume":"17","author":"Pastorino","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib28","first-page":"e149","article-title":"Outcome of molecular targeted agents plus chemotherapy for second-line therapy of metastatic colorectal cancer: a meta-analysis of randomized trials","volume":"15","author":"Pei","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111839","article-title":"Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis","volume":"9","author":"Peng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2023.104034_bib30","first-page":"e631","article-title":"AMALTHEA: prospective, single-arm study of the hellenic cooperative oncology group (HeCOG) evaluating efficacy and safety of first-line FOLFIRI + aflibercept for 6 months followed by aflibercept maintenance in patients with metastatic colorectal cancer","volume":"17","author":"Pentheroudakis","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2023.104034_bib31","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.1007\/s13277-014-2369-z","article-title":"Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis","volume":"35","author":"Qi","year":"2014","journal-title":"Tumor Biol."},{"issue":"183\u2013191","key":"10.1016\/j.critrevonc.2023.104034_bib32","article-title":"Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the global aflibercept safety and health-related quality-of-life program (ASQoP)","volume":"18","author":"Riechelmann","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"issue":"51","key":"10.1016\/j.critrevonc.2023.104034_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2014.10.019","article-title":"Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy","volume":"1990","author":"Ruff","year":"2015","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2023.104034_bib34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1517\/14740338.2015.1057495","article-title":"Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program","volume":"14","author":"Salgado Fern\u00e1ndez","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.critrevonc.2023.104034_bib35","unstructured":"Sanofi, 2016. A Multicenter, Single Arm, Open Label Clinical Trial Evaluating Safety and Health Related Quality of Life of Aflibercept in Combination With Irinotecan\/5-FU Chemotherapy (FOLFIRI) in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen (Clinical trial registration No. results\/NCT01670721). clinicaltrials.gov."},{"key":"10.1016\/j.critrevonc.2023.104034_bib36","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2023.104034_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-021-01625-8","article-title":"Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years","volume":"36","author":"Talks","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.critrevonc.2023.104034_bib38","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol. . J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib39","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104034_bib40","article-title":"The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: a network meta-analysis","volume":"29","author":"Xu","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.critrevonc.2023.104034_bib41","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7314\/APJCP.2016.17.3.973","article-title":"Safety and management of toxicity related to aflibercept in combination with fluorouracil, leucovorin and irinotecan in malaysian patients with metastatic colorectal cancer","volume":"17","author":"Yusof","year":"2016","journal-title":"Asian Pac. J. Cancer Prev. APJCP"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:47:34Z","timestamp":1760903254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":41,"alternative-id":["S1040842823001221"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104034","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104034"}}